GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Total Inventories

NRXS (Neuraxis) Total Inventories : $0.04 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Total Inventories?

Neuraxis's total inventories for the quarter that ended in Dec. 2024 was $0.04 Mil. Neuraxis's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.03 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Neuraxis's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.17.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Neuraxis's Days Inventory for the three months ended in Dec. 2024 was 28.68.

Inventory Turnover measures how fast the company turns over its inventory within a year. Neuraxis's Inventory Turnover for the quarter that ended in Dec. 2024 was 3.18.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Neuraxis's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.04.

Neuraxis Total Inventories Historical Data

The historical data trend for Neuraxis's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Total Inventories Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
0.11 0.04 0.05 0.02 0.04

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.04 0.02 0.04

Neuraxis Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Neuraxis  (AMEX:NRXS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Neuraxis's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

Net-Net Working Capital Per Share (Q: Dec. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.697+0.75 * 0.245+0.5 * 0.044-2.69
-0.004-0)/6.980
=0.17

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Neuraxis's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=0.033/0.105*365 / 4
=28.68

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Neuraxis's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=0.105 / 0.033
=3.18

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Neuraxis's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0.033 / 0.761
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Neuraxis Total Inventories Related Terms

Thank you for viewing the detailed overview of Neuraxis's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuraxis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Total Inventories
Comparable Companies
ABVC OCEA NEUP ATHA SABS TRAW MRKR EDSA SLGL AFMD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
11611 N. Meridian Street, Suite 330, Carmel, IN, USA
Website
http://www.neuraxis.com
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042